home / stock / imvt / imvt news


IMVT News and Press, Immunovant Inc. From 11/14/23

Stock Information

Company Name: Immunovant Inc.
Stock Symbol: IMVT
Market: NASDAQ
Website: immunovant.com

Menu

IMVT IMVT Quote IMVT Short IMVT News IMVT Articles IMVT Message Board
Get IMVT Alerts

News, Short Squeeze, Breakout and More Instantly...

IMVT - Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

2023-11-14 03:48:37 ET Summary Immunovant continues to show promising developments in anti-FcRn platform's clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, could significantly impact the company's valuation an...

IMVT - Immunovant to Present at Upcoming Investor Conferences

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in fireside chats a...

IMVT - Immunovant files automatic mixed shelf

2023-11-09 13:58:12 ET Immunovant ( NASDAQ: IMVT ) filed a prospectus for a mixed shelf offering. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Immunovant files automatic mixed shelf

IMVT - Immunovant GAAP EPS of -$0.45 beats by $0.03

2023-11-09 08:01:02 ET More on Immunovant Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade) Immunovant, Inc. 2023 Q2 - Results - Earnings Call Presentation Imm...

IMVT - Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Positive initial Phase 1 data for IMVT-1402 announced, bolstering best-in-class potential Initial 600 mg multiple-ascending dose (MAD) cohort data for IMVT-1402 expected in November 2023 Initial Phase 2 proof-of-concept data for batoclimab in Graves’ disease expected by end of ...

IMVT - Expected US Company Earnings on Friday, November 3rd, 2023

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...

IMVT - Expected earnings - Immunovant Inc.

Immunovant Inc. (IMVT) is expected to report $-0.46 for Q2 2024

IMVT - Roivant Sciences: Risk-Transforming Deal Met With Crickets

2023-10-24 09:25:49 ET Summary Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a 75% equity interest in Telavant Holdings. Curiously, Roivant Sciences stock sold off on the news...

IMVT - OKTA, AMWL and ORMP among pre-market losers

2023-10-23 08:31:36 ET Losers: Revolution Medicines ( RVMD ) -31% . Troika Media Group ( TRKA ) -21% . Li-Cycle Holdings Corp ( LICY ) -21% announces review of the rochester hub project . Mmtec ( MTC ) -18% . Palatin Technologies ( ...

IMVT - Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 8,475,500 shares of its ...

Previous 10 Next 10